ABSTRACT
PURPOSE: To describe a case of zonisamide-induced bilateral choroidal effusion. CASE REPORT: A 72-year-old woman presented with a 4-day history of bilateral blurred vision 9 days after initiating oral zonisamide for essential tremor. Clinical examination revealed an asymmetric choroidal detachment with open anterior chamber angle and intraocular pressure within the normal range. Posterior segment ultrasonography and ultrasound biomicroscopy both confirmed the presence of bilateral ciliochoroidal effusion. Zonisamide treatment was discontinued. One month after treatment discontinuation, the ophthalmological examination was normal and no further treatment was needed. CONCLUSION: Zonisamide can cause an idiosyncratic reaction leading to choroidal effusion with or without acute angle closure. Early withdrawal of the causative agent is the key to reversing this condition. These findings indicate that zonisamide and other sulfa-derived drugs must be ruled out in the differential diagnosis of choroidal effusion of unknown cause.
Subject(s)
Anticonvulsants/adverse effects , Choroidal Effusions/chemically induced , Zonisamide/adverse effects , Aged , Choroidal Effusions/diagnostic imaging , Female , Humans , Intraocular Pressure , Microscopy, Acoustic , Vision Disorders/chemically induced , Vision Disorders/diagnosisABSTRACT
In recent years, minimally invasive glaucoma surgery has emerged as a novel approach to lowering intraocular pressure. This technique, which is usually reserved for mild to moderate cases, is less invasive than classic filtration surgery and potentially offers a better safety profile. The XEN Gel Stent is implanted through a minimally invasive, ab interno procedure to create a subconjunctival pathway. Conjunctival tissue disruption is minimal, and flow is restricted to avoid hypotony. Data on the optimal approach to managing complications associated with this procedure are limited due to the relatively recent commercialization of this device. Here, we report a case of a persistent leaking bleb caused by XEN Stent exposure, which was managed by ab interno repositioning of the stent through the anterior chamber and direct suturing of the conjunctival defect.
Subject(s)
Anterior Chamber/surgery , Conjunctiva/injuries , Glaucoma Drainage Implants/adverse effects , Glaucoma, Open-Angle/surgery , Reoperation , Rupture/etiology , Surgical Wound Dehiscence/etiology , Conjunctiva/surgery , Female , Glaucoma, Open-Angle/physiopathology , Humans , Intraocular Pressure/physiology , Middle Aged , Minimally Invasive Surgical Procedures/methods , Stents , Surgical Wound Dehiscence/surgery , Tonometry, OcularSubject(s)
Glaucoma, Angle-Closure/etiology , Noonan Syndrome/complications , Acute Disease , Adult , Alkylating Agents/administration & dosage , Female , Glaucoma, Angle-Closure/diagnosis , Glaucoma, Angle-Closure/surgery , Gonioscopy , Humans , Intraocular Pressure , Iridectomy , Iris/surgery , Laser Therapy , Mitomycin/administration & dosage , TrabeculectomyABSTRACT
OBJECTIVE: To determine the medium-term outcome of Ahmed implants inserted through a needle tract at 5 mm from limbus that eliminates the need for a donor scleral graft. METHODS: A retrospective case series of 19 patients undergoing Ahmed implant surgery for refractory glaucoma with a mean follow-up of 12 months. Primary outcome measures included control of intraocular pressure after surgery. Secondary outcome measure included the frequency of intraoperative and postoperative complications. RESULTS: Intraocular pressure was maintained between 6 and 21 mmHg throughout the study. There was no postoperative hypotony. There were no complications related to this modified technique. CONCLUSION: Needle tract at 5 mm from limbus maintains implant's ability to control intraocular pressure and eliminates the need for a donor scleral graft or heterologous material.
